APA (7th ed.) Citation

Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, . . . Victor M. Santana. (2020). A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, Fariba Navid, and Victor M. Santana. A Phase 1 and Pharmacokinetic Study Evaluating Daily or Weekly Schedules of the Humanized Anti-GD2 Antibody Hu14.18K322A in Recurrent/refractory Solid Tumors. Taylor & Francis Group, 2020.

MLA (9th ed.) Citation

Michael W. Bishop, et al. A Phase 1 and Pharmacokinetic Study Evaluating Daily or Weekly Schedules of the Humanized Anti-GD2 Antibody Hu14.18K322A in Recurrent/refractory Solid Tumors. Taylor & Francis Group, 2020.